Literature DB >> 33430813

Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.

Boran Chen1,2, Chaoyue Chen1,3, Yang Zhang1,2, Jianguo Xu4.   

Abstract

BACKGROUND: The incidence of glioblastoma increases significantly with age. With the growing and aging population, there is a lack of comprehensive analysis of recent glioblastoma incidence trend in the United States. This study aims to provide in-depth description of the patterns of incidence trends and to examine the age-period-cohort effects to the trends of glioblastoma specific to elderly patients.
METHODS: The incidence rates were age-adjusted and reported per 100,000 population. We calculated the annual percent change (APC) in incidence using the Joinpoint Regression Program and conducted an age-period-cohort analysis of elderly glioblastoma reported between 2000 and 2017 to the Surveillance Epidemiology and End Results (SEER) 18 registry database.
RESULTS: The overall incidence rate of elderly patients with glioblastoma was 13.16 per 100,000 (95% CI, 12.99-13.32) from 2000 to 2017. Non-Hispanic whites (20,406, 83.6%) made up the majority. The incidence rate of male was about 1.62 times that of female. The trend of incidence remained stable and there was a non-significant increasing tendency for all elderly patients (APC 0.3, 95% CI, - 0.1 to 0.7, p = 0.111). There was a significantly increasing incidence trend for non-Hispanic white (APC 0.6, 95% CI, 0.2 to 1.1, p = 0.013), supratentorial location (APC 0.7, 95% CI, 0.2 to 1.3, p = 0.016), tumor size < 4 cm (APC 2.5, 95% CI, 1.4 to 3.6, p < 0.001), and a significantly decreasing trend for overlapping/NOS location (APC -0.9, 95% CI, - 1.6 to - 0.2, p = 0.012), and unknown tumor size (APC -4.9, 95% CI, - 6.6 to - 3.3, p < 0.001). The age-period-cohort analysis showed the effect of age on incidence trends (p< 0.001, Wald test), while did not indicate the period and cohort effects of the incidence trends of glioblastoma (p = 0.063 and p =0.536, respectively, Wald test).
CONCLUSION: The overall incidence of glioblastoma in the elderly population remained stable between 2000 and 2017. Period and cohort effects were not evident in the trend of glioblastoma incidence. Future population-based studies exploring the difference in the trend of glioblastoma incidence by specific molecular subgroups are warranted to further our understanding of the etiology of glioblastoma.

Entities:  

Keywords:  Age-adjusted incidence rate; Age-period-cohort analysis; Annual percentage change; Elderly; Glioblastoma; Join-point analysis; SEER

Mesh:

Year:  2021        PMID: 33430813      PMCID: PMC7802341          DOI: 10.1186/s12885-020-07778-1

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  38 in total

Review 1.  Management of glioblastoma: State of the art and future directions.

Authors:  Aaron C Tan; David M Ashley; Giselle Y López; Michael Malinzak; Henry S Friedman; Mustafa Khasraw
Journal:  CA Cancer J Clin       Date:  2020-06-01       Impact factor: 508.702

2.  A web tool for age-period-cohort analysis of cancer incidence and mortality rates.

Authors:  Philip S Rosenberg; David P Check; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-21       Impact factor: 4.254

3.  Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015.

Authors:  Faith G Davis; Trenton R Smith; Haley R Gittleman; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

4.  A population-based study of glioblastoma multiforme.

Authors:  L Paszat; N Laperriere; P Groome; K Schulze; W Mackillop; E Holowaty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma.

Authors:  Lennart Hardell; Michael Carlberg; Kjell Hansson Mild
Journal:  Pathophysiology       Date:  2012-12-21

8.  Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005-2015, using the Central Brain Tumor Registry of the United States.

Authors:  Rebecca L Achey; Haley Gittleman; Julia Schroer; Vishesh Khanna; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

9.  Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study.

Authors:  Mark S Pearce; Jane A Salotti; Mark P Little; Kieran McHugh; Choonsik Lee; Kwang Pyo Kim; Nicola L Howe; Cecile M Ronckers; Preetha Rajaraman; Alan W Sir Craft; Louise Parker; Amy Berrington de González
Journal:  Lancet       Date:  2012-06-07       Impact factor: 79.321

10.  Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States.

Authors:  M P Little; P Rajaraman; R E Curtis; S S Devesa; P D Inskip; D P Check; M S Linet
Journal:  BMJ       Date:  2012-03-08
View more
  7 in total

1.  Blockade of Nuclear Factor-Κb (NF-Κb) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells.

Authors:  Ali Nasrollahzadeh; Majid Momeny; Davood Bashash; Hassan Yousefi; Seyed Asadollah Mousavi; Seyed Hamidollah Ghaffari
Journal:  Rep Biochem Mol Biol       Date:  2022-01

2.  Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.

Authors:  Munki Choo; Van-Hieu Mai; Han Sun Kim; Dong-Hwa Kim; Ja-Lok Ku; Sang Kook Lee; Chul-Kee Park; Yong Jin An; Sunghyouk Park
Journal:  Acta Pharmacol Sin       Date:  2022-09-13       Impact factor: 7.169

Review 3.  Sex-Specific Differences in Glioblastoma.

Authors:  Anna Carrano; Juan Jose Juarez; Diego Incontri; Antonio Ibarra; Hugo Guerrero Cazares
Journal:  Cells       Date:  2021-07-14       Impact factor: 7.666

Review 4.  Multimodal targeting of glioma with functionalized nanoparticles.

Authors:  Hany E Marei
Journal:  Cancer Cell Int       Date:  2022-08-23       Impact factor: 6.429

5.  Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts.

Authors:  Yossi Nishri; Maayan Vatarescu; Ishai Luz; Lior Epstein; Mirta Dumančić; Sara Del Mare; Amit Shai; Michael Schmidt; Lisa Deutsch; Robert B Den; Itzhak Kelson; Yona Keisari; Lior Arazi; Tomer Cooks; Vered Domankevich
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

6.  Geriatric Neuro-Oncology in the Middle East: A Sultanate of Oman Experience.

Authors:  Omar Al-Taei; Abdulrahman Al-Mirza; Tariq Al-Saadi
Journal:  Neurol Int       Date:  2021-05-28

Review 7.  Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles.

Authors:  Gloria Krapež; Katarina Kouter; Ivana Jovčevska; Alja Videtič Paska
Journal:  Biomedicines       Date:  2022-01-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.